RxDoctor Payments Data

Sudha Jogimahanti, MD

Family Medicine · Fort Worth, TXNPI 1649373614

Payments from drug & device makers

$11,267in general payments, 2019–2025

Across 548 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Abbott$897
  • AstraZeneca$799
  • Pfizer$598
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$1,20011%
  • Travel & lodging$3043%
  • Food & beverage$9,59785%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,267 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$127,047
Medicare patients
130
Services billed
3,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$36,860
JanuviaSitagliptin Phosphate23$27,035
FarxigaDapagliflozin Propanediol20$23,756
JardianceEmpagliflozin19$22,085
MounjaroTirzepatide13$15,904
ArexvyRsvpref3 Antigen/As01e/Pf33$10,126
Repatha SureclickEvolocumab16$9,603
ShingrixVaricella-Zoster Ge/As01b/Pf43$9,510
Janumet XrSitagliptin Phos/Metformin Hcl12$9,043
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf46$3,230
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,972
SynthroidLevothyroxine Sodium30$2,727
Atorvastatin Calcium234$1,755
Azelastine Hcl80$1,577
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide47$1,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,323$36,86026 claims
MerckJanuvia, Janumet Xr$167$36,07835 claims
AstraZenecaFarxiga$799$23,75620 claims
Boehringer IngelheimJardiance$543$22,08519 claims
GSKArexvy, Shingrix$144$19,63676 claims
Lilly USA, LLCMounjaro$463$15,90413 claims
AbbVieSynthroid$1,487$2,72730 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$47$1,291121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →